Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | BMS-986403 |
| Trade Name | |
| Synonyms | BMS986403|BMS 986403 |
| Drug Descriptions |
BMS-986403 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets ROR1, which potentially induce toxicity in ROR1-expressing tumor cells (NCI Drug DIctionary). |
| DrugClasses | ROR1 Immune Cell Therapy 5 |
| CAS Registry Number | NA |
| NCIT ID | C192143 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BMS-986403 | BMS-986403 | 0 | 0 |
| BMS-986403 + Cytarabine + Fludarabine | BMS-986403 Cytarabine Fludarabine | 0 | 1 |